Research programme: influenza vaccines - Mymetics/Sanofi
Latest Information Update: 08 Apr 2022
At a glance
- Originator Mymetics Corporation; Sanofi Pasteur
- Developer Mymetics Corporation; Sanofi
- Class Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Influenza virus infections
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in Netherlands (Parenteral)
- 01 Dec 2016 Preclinical trials in Influenza virus infections (Prevention) in Switzerland
- 01 Dec 2016 Mymetics and Sanofi Pasteur agree to co-develop influenza vaccines in Netherlands for Influenza virus infections